...
机译:MM-011的成熟结果:脂质体Doxorubicin,长春新碱,地塞米松和Lenalalomide联合疗法的I / II试验,然后是Lenalidomide维持复发/难治性多发性骨髓瘤
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
Celgene Corporation Summit NJ United States;
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
Brightech International Somerset NJ United States;
Quantitative Health Sciences Cleveland Clinic Cleveland OH United States;
Medical Oncology/Hematology Sparrow Cancer Center Lansing MI United States;
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
UC San Diego Nevada Cancer Institute Las Vegas NV United States;
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
Taussig Cancer Institute Cleveland Clinic Cleveland OH United States;
Celgene Corporation Summit NJ United States;
Celgene Corporation Summit NJ United States;
Department of Hematologic Malignancies H. Lee Moffitt Cancer Center and Research Institute Tampa;
机译:MM-011的成熟结果:脂质体阿霉素,长春新碱,地塞米松和来那度胺联合治疗,然后来那度胺维持治疗复发/难治性多发性骨髓瘤的I / II期试验
机译:德语德语骨髓瘤多中心小组(GMMG)试验ReLApsE的原理和设计:来那度胺/地塞米松与来那度胺/地塞米松联合随后自体干细胞移植和来那度胺维持治疗多发性骨髓瘤患者的随机,开放,多中心III期试验
机译:抢救自体移植和即连续甲胺维持和延长半岛/地塞米松复发多发性骨髓瘤:随机化GMMG阶段III多中心试验结果的结果
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:德语德语骨髓瘤多中心小组(GMMG)试验ReLApsE的原理和设计:来那度胺/地塞米松与来那度胺/地塞米松联合随后自体干细胞移植和来那度胺维持治疗多发性骨髓瘤的患者的随机开放多中心III期试验
机译:德语系骨髓瘤多中心小组(RelepsE)试验的原理和设计:来那度胺/地塞米松与来那度胺/地塞米松联合随后的自体干细胞移植和来那度胺维持治疗多发性骨髓瘤的患者的随机,开放,多中心III期试验